Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by jeffm34on Apr 12, 2021 1:12pm
78 Views
Post# 32978096

RE:RE:RE:RE:RE:RE:Annual meeting

RE:RE:RE:RE:RE:RE:Annual meeting SPCEO1, have to disagree with you there.  That was not a news release to try and increase the share price. The record quarterly sales, NASH phase 3 and start of Oncology had to be made public before the offering could happen.  I think the news release was done in a way to try and keep the share price from running too high above the agreed upon offering price. You can't tell me this was meant to try and increase the share price while announcing the 3 best developments this company has had in years.  If that was an attempt to increase the share price someone should have been fired on the spot:

"Theratechnologies outlines F2020 net revenue estimate

2021-01-07 07:34 ET - News Release"



 



SPCEO1 wrote: My best guess is that the company would not have even said anything about the letter to proceed on the NASH trial if they were not doing the OO. They wanted to put whatever they could out there to get the share price higher before the OO 


<< Previous
Bullboard Posts
Next >>